Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].
Journal: The journal of prevention of Alzheimer's disease
Published: March 14, 2026
Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ+ and Aβ- dementia with Lewy bodies patients.
Journal: Alzheimer's research & therapy
Published: February 05, 2026
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: January 15, 2026
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.
Journal: The journal of prevention of Alzheimer's disease
Published: November 12, 2025
Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 02, 2025
Correction: A natural history study to track brain and spinal cord changes in individuals with Friedreich's ataxia: TRACK-FA study protocol.
Journal: PloS one
Published: May 22, 2025
Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 06, 2025
Correction: A natural history study to track brain and spinal cord changes in individuals with Friedreich's ataxia: TRACK-FA study protocol.
Journal: PloS one
Published: March 18, 2025
Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.
Journal: Annals of neurology
Published: August 14, 2024
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: July 10, 2024
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: December 14, 2023
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
Journal: The journal of prevention of Alzheimer's disease
Published: October 24, 2023
Last Updated: 09/26/2026